Press Releases

Date Title and Summary
Toggle Summary Kezar Life Sciences Closes $23M Series A Financing
Startup to Spin Out Assets From Amgen Subsidiary Onyx, Focus on Innovative New Treatments for Autoimmune Disorders SOUTH SAN FRANCISCO, Calif., June 16, 2015 /PRNewswire/ -- Kezar Life Sciences, a company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune
Toggle Summary Upstart Kezar wrangles $23M to pick up where Onyx left off
Toggle Summary Kezar scores with new way to tackle autoimmune diseases
Toggle Summary The 10 Hottest Bay Area Biotech Startups
Toggle Summary Kezar Life Sciences Announces Initiation of Phase 1 Clinical Program for Lead Candidate KZR-616, a First-in-Class Immunoproteasome Inhibitor
Kezar expects to report topline pharmacokinetics and target engagement data by year-end 2016 SOUTH SAN FRANCISCO, Calif., Sept. 13, 2016 /PRNewswire/ -- Kezar Life Sciences, a company focused on the discovery and development of drugs targeting protein homeostasis, announced today the initiation of
Toggle Summary Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Funding to support continued development of KZR-616, a first-in-class immunoproteasome inhibitor, and advance discovery program targeting the protein secretion pathway SOUTH SAN FRANCISCO, Calif., July 25, 2017 /PRNewswire/ -- Kezar Life Sciences, a private, clinical-stage biopharmaceutical company
Toggle Summary Kezar Life Sciences to Present Multiple Abstracts at the 2017 American College of Rheumatology Annual Meeting in San Diego
Kezar Scientific Leaders to discuss Phase 1a data with KZR-616, animal model results, and new insights into immunoproteasome biology during the ACR 2017 Annual Meeting SOUTH SAN FRANCISCO, Oct. 31, 2017 /PRNewswire/ --Kezar Life Sciences, a private, clinical-stage biopharmaceutical company
Toggle Summary Kezar Life Sciences to Present at 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2018 /PRNewswire/ -- Kezar Life Sciences, a private, clinical-stage biopharmaceutical company developing novel small molecule therapeutics, today announced that John Fowler, Chief Executive Officer, will present at the 36th Annual J.P.
Toggle Summary Kezar Life Sciences Strengthens Management Team
SOUTH SAN FRANCISCO, Calif., May 1, 2018 /PRNewswire/ -- Kezar Life Sciences, a private, clinical-stage biotechnology company discovering and developing novel small molecule therapeutics, today announced the appointments of Niti Goel, MD, as Chief Medical Officer and Marc Belsky as Chief Financial
Toggle Summary Kezar Life Sciences Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif. , June 20, 2018 /PRNewswire/ --  Kezar Life Sciences, Inc. ( Nasdaq:KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today that it has priced its initial